Inicio › Leucemia › Texas › Houston
Ensayos clínicos de Leucemia en Houston, TX
28 estudios para Leucemia buscan participantes en centros de Houston y alrededores (a unos 30 millas). Abra un estudio para ver quién puede participar y cómo contactar con el equipo.
Texto oficial del estudio (inglés)
Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
ReclutandoFase 3
- Quetzal Site 6, Houston
Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia
ReclutandoFase 2
- M D Anderson Cancer Center, Houston
Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY)
ReclutandoFase 1
- Texas Children's Hospital, Houston
- The Methodist Hospital, Houston
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
ReclutandoFase 2
- The Methodist Hospital Research Institute, Houston
- The University of Texas MD Anderson Cancer Center, Houston
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
ReclutandoFase 2
- The University of Texas MD Anderson Cancer Center, Houston
A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes
ReclutandoFase 2
- MD Anderson Cancer Center, Houston
Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
ReclutandoFase 3
- Research Site, Houston
First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect.
ReclutandoFase 1
- Texas Children's Hospital, Houston
Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
ReclutandoFase 1/2
- MD Anderson Cancer Center, Houston
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
ReclutandoFase 1
- MD Anderson Cancer Center, Houston
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
ReclutandoFase 3
- University of Texas, Houston
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
ReclutandoFase 1/2
- Research Site, Houston
Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
ReclutandoFase 2
- Baylor Texas Children's Hospital, Houston
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
ReclutandoFase 1/2
- University of Texas MD Anderson Cancer Center, Houston
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
ReclutandoFase 2
- University of Texas MD Anderson Cancer Center, Houston
CD4CAR for CD4+ Leukemia and Lymphoma
ReclutandoFase 1
- The University of Texas MD Anderson Cancer Center, Houston
A Study of Revumenib and Mezigdomide in People With Leukemia
ReclutandoFase 1/2
- MD Anderson Cancer Center (Data Collection Only), Houston
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
ReclutandoFase 1/2
- Dren Investigational Site, Houston
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
ReclutandoEstudio observacional
- Texas Children's Hospital, Houston
Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies
ReclutandoEstudio observacional
- M D Anderson Cancer Center, Houston
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
ReclutandoEstudio observacional
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
ReclutandoFase 2/3
- MD Anderson Cancer Center, Houston
Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)
ReclutandoFase 2
- M D Anderson Cancer Center, Houston
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
ReclutandoFase 1
- MD Anderson Cancer Center, Houston
Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia
ReclutandoFase 1
- The University of Texas MD Anderson Cancer Center, Houston
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
ReclutandoEstudio observacional
- Massive Bio SYNERGY-AI site, Houston
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
ReclutandoFase 1
- The University of Texas M.D. Anderson Cancer Center, Houston
Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
ReclutandoFase 1
- MD Anderson Cancer Center, Houston
Más información sobre Leucemia en MedlinePlus
Ensayos de Leucemia en otras ciudades
- Boston, MA25 estudios
- New York City, NY19 estudios
- Los Angeles, CA16 estudios
- Chicago, IL16 estudios
- Durham, NC13 estudios
- Nashville, TN12 estudios
- Baldwin Park, CA12 estudios
- Columbus, OH12 estudios
- Philadelphia, PA12 estudios
- Seattle, WA11 estudios
- Milwaukee, WI11 estudios
- Birmingham, AL10 estudios
Otros estudios en Houston
- Cáncer de pulmón de células no pequeñas145 estudios
- Cáncer de seno126 estudios
- Cáncer (todos los tipos)122 estudios
- Cáncer metastásico104 estudios
- Cáncer del colon y del recto103 estudios
- Cáncer de ovario90 estudios
- Leucemia mielógena aguda86 estudios
- Cáncer de pulmón78 estudios
- Cáncer de próstata76 estudios
- Cáncer de endometrio69 estudios
- Cáncer de páncreas62 estudios
- Melanoma59 estudios
De ClinicalTrials.gov, datos obtenidos el 1 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.